Earnings Feed
Start Free
Home/Filings/4/0001209191-24-001334
4//SEC Filing

Taich Adam 4

Accession 0001209191-24-001334

CIK 0001837412other
View on SEC.govCompany Profile

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 9:54 PM ET

Size

34.7 KB

Accession

0001209191-24-001334

Insider Transaction Report

Form 4
Period: 2024-01-05
SomaLogic, Inc.SLGC
Taich Adam
Interim CEO
Transactions
  • Disposition to Issuer

    Stock Option (Right to buy)

    2024-01-05−145,000→ 0 total
    Exercise: $3.79Exp: 2032-09-12→ Common Stock (145,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2024-01-05−150,000→ 0 total
    Exercise: $2.30Exp: 2033-03-16→ Common Stock (150,000 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    2024-01-05−13,875→ 0 total
    → Common Stock (13,875 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    2024-01-05−53,250→ 0 total
    → Common Stock (53,250 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2024-01-05−185,812→ 0 total
    Exercise: $13.27Exp: 2031-11-09→ Common Stock (185,812 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2024-01-05−95,000→ 0 total
    Exercise: $2.33Exp: 2033-03-23→ Common Stock (95,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2024-01-05−855,000→ 0 total
    Exercise: $2.74Exp: 2033-06-07→ Common Stock (855,000 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    2024-01-05−25,000→ 0 total
    → Common Stock (25,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2024-01-05−110,000→ 0 total
    Exercise: $9.08Exp: 2032-02-29→ Common Stock (110,000 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-05−48,425→ 0 total
  • Disposition to Issuer

    Restricted Stock Unit

    2024-01-05−98,093→ 0 total
    → Common Stock (98,093 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    2024-01-05−592,000→ 0 total
    → Common Stock (592,000 underlying)
Footnotes (16)
  • [F1]On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").
  • [F10]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.
  • [F11]The RSUs vest as to 1/4th of the total grant on each of March 1, 2023, March 1, 2024, March 1, 2025 and March 1, 2026, subject to the continued service of the Reporting Person on each vesting date.
  • [F12]Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.
  • [F13]The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date.
  • [F14]The RSUs vest as to 1/4th of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025 and September 13, 2026, subject to the continued service of the Reporting Person on each vesting date.
  • [F15]The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date.
  • [F16]The RSUs vest as to 1/4th of the total grant on each of June 8, 2024, June 8, 2025, June 8, 2026 and June 8, 2027, subject to the continued service of the Reporting Person on each vesting date.
  • [F2](Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
  • [F3]The option vested as to 1/4th of the total grant on November 10, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
  • [F4]Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.
  • [F5]The option vested as to 1/4th of the total grant on March 1, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
  • [F6]The option vested as to 1/4th of the total grant on September 13, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
  • [F7]The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
  • [F8]The option vests as to 1/4th of the total grant on March 24, 2024, and thereafter 1/20th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
  • [F9]The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

Documents

1 file

Issuer

SomaLogic, Inc.

CIK 0001837412

→
Entity typeother

Related Parties

1
  • filerCIK 0001971187

Filing Metadata

Form type
4
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 9:54 PM ET
Size
34.7 KB
View on SEC.gov